Key facts
- It has raised $400K; the latest was Angel (individual) ($80K) in Sep 2025.
- Notable investors include ACS BrightEdge, Cancer HackerLab Accelerator, Merck Digital Sciences Studio.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Nine Diagnostics
- ·The full record, as it builds
Funding rounds
No funding rounds for Nine Diagnostics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Nine Diagnostics
Developer of a functional precision medicine technology designed to detect health abnormalities and signals of treatment effectiveness in small patient samples. The company uses artificial intelligence and nanosensor technologies to develop holistic profiles based on a patient's personal health data, demographics, social determinants of health, cancer detection, and other relevant factors pertinent to the ultimate outcomes, enabling clients to select and optimize treatments for individual patients.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2024
- Employees
- 3
- Website
- ninediagnostics.xyz/
- Ownership
- Privately Held (backing)
Nine Diagnostics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Nine Diagnostics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Nine Diagnostics in its N-PORT filings yet. We sweep new filings monthly.